Maurizio R. Zangari

Hematology

4301 W Markham St
Little Rock, AR 72205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: August 07, 2026

Necrobiotic Xanthogranuloma Associated With IgG Kappa Smoldering Myeloma Presenting as Vision-Threatening Orbital Disease: Clinical Response to Plasma Cell-Directed Therapy.

Necrobiotic Xanthogranuloma Associated With IgG Kappa Smoldering Myeloma Presenting as Vision-Threatening Orbital Disease: Clinical Response to Plasma Cell-Directed Therapy.

Journal: Cureus

Published: June 19, 2026

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Journal: Cancers

Published: June 16, 2026

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: April 17, 2026

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: November 30, 2025

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: September 08, 2025

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Journal: Blood cancer journal

Published: July 01, 2025

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.

Journal: Cancer biomarkers : section A of Disease markers

Published: June 09, 2025

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.

Journal: JAMA oncology

Published: June 05, 2025

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.

Journal: Blood cancer journal

Published: May 30, 2025

Heavy Chain Cast Nephropathy in a Gamma Heavy Chain Disease: RESPONSE to High-Dose Therapy Melphalan and Daratumumab.

Heavy Chain Cast Nephropathy in a Gamma Heavy Chain Disease: RESPONSE to High-Dose Therapy Melphalan and Daratumumab.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 19, 2025

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia.

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia.

Journal: Blood advances

Published: April 01, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026